0867.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 10:08):

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China...

Stats
Dagens volum	6.47M
Gjennomsnittsvolum	7.43M
Markedsverdi	17.65B
EPS	HKD0 ( 2024-03-26 )
Last Dividend	HKD0.342 ( 2023-09-11 )
Next Dividend	HKD0 ( N/A )
P/E	6.79
ATR14	HKD0.00900 (0.13%)

Volum Korrelasjon

Lang: 0.19 (neutral)

Kort: 0.30 (neutral)

Signal:(52.974) Neutral

China Medical System Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

China Medical System Korrelasjon - Valuta/Råvare

0.50
( weak )

0.54
( weak )

0.00
( neutral )

0.52
( weak )

0.00
( neutral )

0.31
( neutral )

China Medical System Økonomi

Annual	2023
Omsetning:	HKD8.01B
Bruttogevinst:	HKD6.11B (76.24 %)
EPS:	HKD0.980

FY	2023
Omsetning:	HKD8.01B
Bruttogevinst:	HKD6.11B (76.24 %)
EPS:	HKD0.980

FY	2022
Omsetning:	HKD9.15B
Bruttogevinst:	HKD7.04B (76.89 %)
EPS:	HKD1.330

FY	2021
Omsetning:	HKD8.34B
Bruttogevinst:	HKD6.25B (74.93 %)
EPS:	HKD1.221

Financial Reports:

No articles found.

China Medical System Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.337 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.274 (N/A)	HKD0.342 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

China Medical System Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.69 - good (96.92%) | Divividend Growth Potential Score: 5.90 - Stable (17.95%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.00693	2011-03-22
Last Dividend	HKD0.342	2023-09-11
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	26	--
Total Paid Out	HKD3.99	--
Avg. Dividend % Per Year	0.00%	--
Score	3.6	--
Div. Sustainability Score	9.69
Div.Growth Potential Score	5.90
Div. Directional Score	7.79	--

Next Divdend (Est)
(2024-07-05)

HKD0.359 Estimate 12.45 %

Dividend Stability

0.50 Below Average

Dividend Score

3.60

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3939.HK	Ex Dividend Junior	2023-06-07	Annually	0.00%
1776.HK	Ex Dividend Junior	2023-07-11	Annually	0.00%
0817.HK	Ex Dividend Junior	2023-09-18	Semi-Annually	0.00%
2359.HK	Ex Dividend Knight	2023-06-05	Annually	0.00%
1345.HK	Ex Dividend Junior	2023-10-04	Semi-Annually	0.00%
0390.HK	Ex Dividend Junior	2023-07-19	Annually	0.00%
6626.HK	Ex Dividend Knight	2023-09-04	Annually	0.00%
1897.HK	Ex Dividend Knight	2023-07-05	Semi-Annually	0.00%
0921.HK	Ex Dividend Junior	2023-07-10	Sporadic	0.00%
0052.HK	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.300	1.500	4.01	6.01	[0 - 0.5]
returnOnAssetsTTM	0.135	1.200	5.49	6.58	[0 - 0.3]
returnOnEquityTTM	0.152	1.500	9.42	10.00	[0.1 - 1]
payoutRatioTTM	0.567	-1.000	4.33	-4.33	[0 - 1]
currentRatioTTM	4.29	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.85	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.10	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0734	-1.500	8.78	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	1.021	2.00	9.66	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.010	2.00	9.50	10.00	[0 - 20]
debtEquityRatioTTM	0.0839	-1.500	9.66	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.758	1.000	0.696	0.696	[0.2 - 0.8]
operatingProfitMarginTTM	0.339	1.000	5.23	5.23	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.923	1.000	0.429	0.429	[0.2 - 2]
assetTurnoverTTM	0.452	0.800	-0.320	-0.256	[0.5 - 2]
Total Score				9.69

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	6.80	1.000	9.41	0	[1 - 100]
returnOnEquityTTM	0.152	2.50	9.63	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.010	2.00	9.66	10.00	[0 - 30]
dividendYielPercentageTTM	9.25	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.021	2.00	9.66	10.00	[0 - 30]
payoutRatioTTM	0.567	1.500	4.33	-4.33	[0 - 1]
pegRatioTTM	0.337	1.500	-1.087	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.312	1.000	4.69	0	[0.1 - 0.5]
Total Score				5.90

China Medical System

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.